PENTA18: A study of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antiretroviral therapy in human immunodeficiency virus-1 (HIV-1) infected children.

Trial Profile

PENTA18: A study of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antiretroviral therapy in human immunodeficiency virus-1 (HIV-1) infected children.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 28 Nov 2015

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Pharmacokinetics; Therapeutic Use
  • Acronyms KONCERT; PENTA-18; PENTA18
  • Most Recent Events

    • 28 Nov 2015 Results published in the AIDS
    • 06 Mar 2014 Primary endpoint 'Viral-load' has not been met.
    • 06 Mar 2014 Results presented at the 21st Conference on Retroviruses and Opportunistic Infections.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top